<DOC>
	<DOCNO>NCT00880750</DOCNO>
	<brief_summary>This study conduct assess potential difference absorption excretion two lanthanum carbonate formulation . This study also do ass safety tolerability two lanthanum carbonate formulation .</brief_summary>
	<brief_title>Pharmacodynamic Study Two Lanthanum Carbonate Formulations Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Inclusion Criteria Ability provide inform consent participate study . Healthy volunteer , age 1855 inclusive . Subject must willing comply applicable contraceptive requirement protocol Female subject must negative pregnancy test Ability chew swallow dos investigational product prescribe protocol . Ability fully comply study procedure restriction , include consumption food provide resident CRC . Exclusion Criteria Current relevant previous history physical psychiatric illness , medical disorder may require treatment make subject unlikely fully complete study , condition present undue risk investigational product study procedure . Clinically significant abnormal serum phosphate level , outside normal limit . Current use medication exception hormonal replacement therapy hormonal contraceptive within 7 day first dose investigational product . A known history lactose intolerance allergy milk food . Clinically significant multiple allergy determine Investigator . History alcohol substance abuse within last 6 month . A positive screen alcohol drug abuse . Male subject consume 21 unit alcohol per week three unit per day . Female subject consume 14 unit alcohol per week two unit per day . A positive human immunodeficiency virus ( HIV ) antibody screen , Hepatitis B surface antigen ( HBsAg ) Hepatitis C virus ( HCV ) antibody screen . Female subject pregnant ( positive pregnancy test ) , lactate , less 90 day postpartum . Subjects previously randomize study . Use tobacco form nicotinecontaining product form . Exusers must report stop use tobacco least 60 day prior receive first dose investigational product . Routine consumption two unit caffeine per day subject experience caffeine withdrawal headache . Donation blood blood product within 60 day prior receive first dose investigational product . Plasma donation within 28 day prior first dose investigational product . Use another investigational product within 30 day prior receive first dose investigational product active enrolment another drug vaccine clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>End stage Renal disease</keyword>
</DOC>